Shares of Geron (GERN) are up 9% in premarket trading.
Behind the move looks to be an article outlining a Mayo Clinic study which says imetelstat "has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis."
The study's lead author calls the results "early but promising."
Amusingly, the article appears to have been posted ahead of its scheduled release from embargo.
Full article is here